A series of articles on bacterial meningitis in The Lancet, the general medical journal, demonstrates
our work in Malawi is in line with current thinking. The articles highlight the lack of pre- and post-vaccine data from low-and middle-income countries, where the disease burden from bacterial meningitis is greatest, and where vaccine introduction has been most recent or is yet to occur.
The authors, from Australia, the United States, the United Kingdom and the Netherlands, say governments and charities will need to step up their involvement in controlled trials of new bacterial meningitis treatments in resource poor countries so early and accurate diagnosis can be implemented with effective antibiotics.
Posted in Action Meningitis by Meningitis Research Foundation on 26 November 2012
Bookmark